Clinical trial
A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of the LB03002 a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Daily Therapy in Treatment Naive Children With Growth Failure Due to Insufficient Secretion of Endogenous Growth Hormone
NCT00271518 is registered in ClinicalTrials.gov with LG Life Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of the LB03002 a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Daily Therapy in Treatment Naive Children With Growth Failure Due to Insufficient Secretion of Endogenous Growth Hormone
- Lead sponsor
- LG Life Sciences
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- September 30, 2005
- Completion date
- Not reported
- Enrollment
- 144 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
growth hormone deficiency (ghd)